Commercial/Healthcare Exchange PA Criteria

Effective: July 24, 2019

Prior Authorization: Evekeo-ODT

Products Affected: Evekeo-ODT orally disintegrating tablet

Medication Description: Amphetamine sulfate is an orally administered central nervous system (CNS) stimulant used primarily to treat attention-deficit hyperactivity disorder (ADHD). Stimulants, such as amphetamine, are highly effective in the treatment of ADHD and are considered first-line therapy.

Covered Uses: Attention Deficit Hyperactivity Disorder (ADHD)

Exclusion Criteria:

1. Receiving concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MOAI
2. Hypersensitivity to amphetamine

Required Medical Information:

1. Diagnosis
2. Past medication trials

Age Restrictions: Patient must be 6 to 17 years of age

Prescriber Restrictions: N/A

Coverage Duration: 1 year

Other Criteria:

1. **Attention Deficit Disorder with Hyperactivity**

   A) Patient has previous use of **2** preferred stimulants used in the treatment of ADHD (preferred stimulants include: Amphetamine/Dextroamphetamine IR/ER Tablets or Capsules, Dextroamphetamine Sulfate IR/ER, Dexmethylphenidate IR/ER/XR, Methylphenidate IR/CD/ER/ER Chew); **AND**

   B) Patient does not currently have contraindication to use of stimulants; **AND**

   C) Patient is 6 to 17 years old

References:

1. Product Information: EVEKEO ODT(TM) orally disintegrating tablets, amphetamine sulfate orally disintegrating tablets. Arbor Pharmaceuticals LLC (per FDA), Atlanta, GA, 2019.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	7/24/19